

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Release of Second Lien Security Interest in Trademarks

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Bank of America, N.A.		05/03/2007	National Association:

RECEIVING PARTY DATA

Name:	Graceway Pharmaceuticals, LLC
Street Address:	340 Edgemont Avenue
Internal Address:	Suite 500
City:	Bristol
State/Country:	TENNESSEE
Postal Code:	37620
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE

Name:	Chester Valley Pharmaceuticals, LLC
Street Address:	2 West Liberty Blvd.
Internal Address:	Suite 203
City:	Malvern
State/Country:	PENNSYLVANIA
Postal Code:	19355
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE

PROPERTY NUMBERS Total: 12

Property Type	Number	Word Mark
Registration Number:	2053136	ALDARA
Registration Number:	0962509	ALU-CAP
Registration Number:	2181399	
Registration Number:	1523151	MAXAIR
Registration Number:	1540056	MINITRAN
Registration Number:	0697028	NORFLEX

CH \$315.00 2053136

Registration Number:	0771046	NORGESIC
Registration Number:	1202505	TAMBOCOR
Serial Number:	78855435	MAXAIR
Serial Number:	78893274	CVP
Serial Number:	78651054	BENZELLE
Serial Number:	78647931	BENZIQ

CORRESPONDENCE DATA

Fax Number: (202)756-9299

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 8002210770

Email: matthew.mayer@thomson.com

Correspondent Name: Corporation Service Company

Address Line 1: 1133 Avenue of the Americas

Address Line 2: Suite 3100

Address Line 4: New York, NEW YORK 10036

ATTORNEY DOCKET NUMBER:	CSC # 889223
NAME OF SUBMITTER:	Matthew Mayer
Signature:	/Matthew Mayer/
Date:	05/10/2007

Total Attachments: 4

source=BOA_graceway_2nd_tm12#page3.tif

source=BOA_graceway_2nd_tm12#page4.tif

source=BOA_graceway_2nd_tm12#page5.tif

source=BOA_graceway_2nd_tm12#page6.tif

RELEASE OF SECOND LIEN SECURITY INTEREST IN TRADEMARKS

THIS RELEASE OF SECURITY INTEREST IN TRADEMARKS (this "Release") is made as of May 3, 2007 (the "Effective Date") among GRACEWAY PHARMACEUTICALS, LLC, a Delaware limited liability company, with offices located at 340 Edgemont Avenue, Suite 500, Bristol, TN 37620 and CHESTER VALLEY PHARMACEUTICALS, LLC, a Delaware limited liability company with offices located at 2 West Liberty Boulevard, Suite 203, Malvern, PA 19355 (each individually a "Grantor" and together the "Grantors") and BANK OF AMERICA, N.A., with offices located at Mail Code: NC1-001-15-14, 101 N. Tyron Street, Charlotte, NC 28255-0001, as second lien collateral agent (in such capacity, the "Collateral Agent") for the Secured Parties.

WHEREAS, pursuant to the terms and conditions of that certain Second Lien Security Agreement, dated as of December 29, 2006 among the Grantors and the Collateral Agent (the "Security Agreement"; all capitalized terms used but not defined herein shall have the respective meanings ascribed thereto in the Security Agreement or the Second Lien Trademark Security Agreement, as applicable), the Grantors granted to the Collateral Agent a continuing security interest in all of their right, title, interest and good will in and to the trademarks, including without limitation the trademark registrations and applications set forth on Schedule B hereto (collectively, the "Trademarks"), together with the goodwill associated therewith;

WHEREAS, the Security Agreement relating to the Trademarks (the "Second Lien Trademark Security Agreement") was recorded with the Trademarks Division of the U.S. Patent & Trademark Office on March 23, 2007, at Reel 3506 and Frame 0506.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby terminates the Second Lien Trademark Security Agreement, and hereby terminates, cancels, re-pledges, reassigns and releases any and all security interests it has against the Trademark Collateral together with the goodwill associated therewith.

If and to the extent the Collateral Agent has acquired any right, title or interest to any of the Trademark Collateral, it hereby assigns and transfers such rights, title or interest to the Grantors.

The Collateral Agent shall take all further actions, and provide to the Grantors and each of their respective successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), requested by the Grantors to more fully and effectively effectuate the purposes of this Release.

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date:


BANK OF AMERICA, N.A.,
as Collateral Agent

By: 
Name: Alysa Trakas
Title: Vice President


[Second Lien Trademark Release]

ACCEPTED AND ACKNOWLEDGED BY:

GRACEWAY PHARMACEUTICALS, LLC

By: 
Name: John A. A. Bellamy
Title: Executive Vice President

CHESTER VALLEY PHARMACEUTICALS, LLC

By: 
Name: John A. A. Bellamy
Title: Executive Vice President

[Second Lien Trademark Release]

Schedule B

UNITED STATES TRADEMARKS:

Registrations:

<u>OWNER</u>	<u>REGISTRATION NUMBER</u>	<u>TRADEMARK</u>
Graceway Pharmaceuticals, LLC	2053136	ALDARA
Graceway Pharmaceuticals, LLC	962509	ALU-CAP
Graceway Pharmaceuticals, LLC	2181399	DESIGN (LEAF)
Graceway Pharmaceuticals, LLC	1523151	MAXAIR
Graceway Pharmaceuticals, LLC	1540056	MINITRAN
Graceway Pharmaceuticals, LLC	697028	NORFLEX
Graceway Pharmaceuticals, LLC	771046	NORGESIC
Graceway Pharmaceuticals, LLC	1202505	TAMBOCOR

Applications:

<u>OWNER</u>	<u>APPLICATION NUMBER</u>	<u>TRADEMARK</u>
Graceway Pharmaceuticals, LLC	78/855435	MAXAIR
Chester Valley Pharmaceuticals, LLC	78/893274	CVP (stylized and/or with design)
Chester Valley Pharmaceuticals, LLC	78/651054	BENZELLE
Chester Valley Pharmaceuticals, LLC	78/647931	BENZIQ